Eloxx Pharmaceuticals (ELOX) News Today → The #1 lithium battery stock to have on your radar in 2024! (From Smallcaps Daily) (Ad) Free ELOX Stock Alerts $0.86 +0.01 (+1.18%) (As of 05/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEloxx Pharmaceuticals Inc (ELOX)investing.com - April 24 at 9:11 AMDelveInsight Business Research, LLP: Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsightfinanznachrichten.de - April 17 at 5:53 PMAlport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsightfinance.yahoo.com - April 17 at 5:53 PMEloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updatesglobenewswire.com - April 16 at 7:30 AMGene therapy and glycoside drugs offer new hope for polycystic kidney disease treatmentmsn.com - April 5 at 1:12 AMNasdaq Inc. Buy Rating: EPS Growth, Valuation Expansion, and Strong FinTech Prospectsmarkets.businessinsider.com - March 26 at 7:42 AMAlmirall, S.A.: Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseasesfinanznachrichten.de - March 13 at 6:29 PMAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseasesglobenewswire.com - March 13 at 11:42 AMAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseasesbusinesswire.com - March 13 at 11:33 AMEloxx Pharmaceuticals Stock (OTC:ELOX), Short Interest Reportbenzinga.com - February 22 at 2:03 PMVertex Pharmaceuticals Inc.barrons.com - February 16 at 11:44 PMEloxx Pharmaceuticals, Inc. (ELOX)finance.yahoo.com - February 6 at 10:48 AMCNS Pharmaceuticals prices $4M public offeringmsn.com - January 30 at 5:44 AMAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Regeneron (REGN)markets.businessinsider.com - December 23 at 9:39 AMAnalysts Offer Insights on Healthcare Companies: Shockwave Medical (SWAV), Annexon Biosciences (ANNX) and United Therapeutics (UTHR)markets.businessinsider.com - December 21 at 8:22 PMOff the Beaten Path: 3 Delisted Stocks for The Speculative Investorfinance.yahoo.com - December 13 at 2:31 AMAnalysts Offer Insights on Healthcare Companies: Lumos Pharma (LUMO), Crispr Therapeutics AG (CRSP) and Biomea Fusion (BMEA)markets.businessinsider.com - December 11 at 11:19 PMAnalysts Conflicted on These Healthcare Names: Biomea Fusion (BMEA) and Medtronic (MDT)markets.businessinsider.com - November 22 at 8:35 PMHoth stock jumps on positive FDA feedback on drug HT-KITmsn.com - November 14 at 9:57 AMEloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Updatefinance.yahoo.com - November 13 at 4:38 PMEloxx Pharmaceuticals Inc ELOXmorningstar.com - November 8 at 1:14 AMEloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuriafinance.yahoo.com - October 9 at 8:59 AMEloxx Pharmaceuticals prices $2M stock offeringseekingalpha.com - September 21 at 5:48 PMEloxx Pharmaceuticals Announces Registered Direct Offering - Quick Factsmarkets.businessinsider.com - September 19 at 9:35 AMEloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - September 19 at 9:35 AMEloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndromefinance.yahoo.com - September 18 at 8:52 AMEloxx moves ahead with plans with gene therapy for rare kidney disordermsn.com - September 8 at 3:43 PMEloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013finance.yahoo.com - September 7 at 9:34 AMEloxx Pharmaceuticals (NASDAQ: ELOX)fool.com - August 30 at 2:14 PMEloxx reports all patients in Phase II Alport syndrome trial have improvedmsn.com - August 15 at 7:27 AMEloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Updatemarkets.businessinsider.com - August 14 at 9:25 PMEloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndromefinance.yahoo.com - August 14 at 11:23 AMEloxx Pharma (NASDAQ:ELOX) Rises On Promising Phase 2 Data In Alport Syndromemsn.com - August 14 at 11:23 AMEloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndromefinance.yahoo.com - August 14 at 11:23 AMThis Small Cap Stock Surged Over 100%marketbeat.com - July 12 at 10:52 AMEloxx, Airbnb, Tesla, PainReform, Roku: Why These 5 Stocks Are Drawing Investor Attention Todaymsn.com - July 11 at 11:06 PMEloxx Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Up 111.3%benzinga.com - July 11 at 6:05 PMOppenheimer Maintains Eloxx Pharmaceuticals (ELOX) Outperform Recommendationmsn.com - July 11 at 3:48 PMmarketbeat.com - July 11 at 3:17 PMWhy Eloxx Pharmaceuticals (ELOX) Stock Is Soaring Tuesdaybenzinga.com - July 11 at 1:04 PMOppenheimer Maintains Outperform on Eloxx Pharmaceuticals, Raises Price Target to $55benzinga.com - July 11 at 10:47 AMmarketbeat.com - July 11 at 10:44 AMmarketbeat.com - July 11 at 9:41 AMEloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefitfinance.yahoo.com - July 10 at 10:08 AMEloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02finance.yahoo.com - June 28 at 9:43 AMEloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndromefinance.yahoo.com - June 21 at 2:28 PMEloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congressfinance.yahoo.com - June 21 at 9:27 AMFinal Data Report: Eloxx Touts Improved Lung Function For Cystic Fibrosis Candidatebenzinga.com - June 15 at 12:32 PMEloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patientsfinance.yahoo.com - June 14 at 6:51 PMNasdaq grants extension to Eloxx Pharmaceuticals to regain compliancemsn.com - June 6 at 9:48 AM Get Eloxx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter. Email Address Incredible Opportunity to Retire FAST! (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market. Click here to get instant access to the guide ELOX Media Mentions By Week ELOX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELOX News Sentiment▼0.000.39▲Average Medical News Sentiment ELOX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELOX Articles This Week▼01▲ELOX Articles Average Week Get Eloxx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Avalon GloboCare News Today Kiromic BioPharma News Today Gamida Cell News Today Finch Therapeutics Group News Today TRACON Pharmaceuticals News Today SQZ Biotechnologies News Today TC Biopharm News Today Palisade Bio News Today Scinai Immunotherapeutics News Today Acorda Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELOX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyAI “wealth window” is closing June 25thParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
